Ekso Bionics (EKSO) COO adds 1,308 shares through 401(k) matching purchase

Rhea-AI Filing Summary

Ekso Bionics Holdings Chief Operating Officer Jason C. Jones increased his ownership through a small share acquisition tied to the company’s retirement plan. He acquired 1,308 shares of common stock on March 16, 2026 at $11.85 per share in an open-market purchase recorded under his 401(k) account, as part of the issuer’s 401(k) contribution matching program.

After this transaction, he indirectly holds 4,449 shares through the 401(k) and directly holds 25,621 shares of common stock. The share amounts disclosed have been adjusted to reflect a prior 1-for-15 reverse stock split.

Insider Trade Summary

Net Buyer: 1,308 shares ($15,500)

Net Buy 2 txns

Insider Jones Jason C

Role Chief Operating Officer

Bought 1,308 shs ($15K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,308	$11.85	$15K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 4,449 shares (Indirect, By 401(k)); Common Stock — 25,621 shares (Direct)

Footnotes (1)

1. These shares of common stock were acquired in connection with the Issuer's 401(k) contribution matching program. On June 2, 2025, the Issuer effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones Jason C

(Last) (First) (Middle)

101 GLACIER POINT

SUITE A

(Street)

SAN RAFAEL CALIFORNIA 94901

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EKSO BIONICS HOLDINGS, INC. [ EKSO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		P		1,308(1)	A	$11.85	4,449(2)	I	By 401(k)
Common Stock								25,621(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were acquired in connection with the Issuer's 401(k) contribution matching program.

2. On June 2, 2025, the Issuer effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

	/s/ Jerome Wong	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Ekso Bionics (EKSO) COO Jason C. Jones do in this Form 4 filing?

Jason C. Jones increased his Ekso Bionics holdings. He acquired 1,308 shares of common stock on March 16, 2026 at $11.85 per share, recorded in his 401(k) account under the company’s contribution matching program, and updated his total direct and indirect ownership.

How many Ekso Bionics (EKSO) shares does Jason C. Jones own after this transaction?

After the reported activity, Jason C. Jones indirectly holds 4,449 Ekso Bionics shares through a 401(k) and directly holds 25,621 shares. These figures reflect a previously effected 1-for-15 reverse stock split that adjusted all amounts reported in this Form 4 filing.

What was the purchase price for the Ekso Bionics (EKSO) shares in this Form 4?

The reported Ekso Bionics shares were acquired at $11.85 per share. The transaction involved 1,308 shares of common stock on March 16, 2026, recorded as an open-market purchase linked to the issuer’s 401(k) contribution matching program for Chief Operating Officer Jason C. Jones.

Is the Ekso Bionics (EKSO) Form 4 transaction a direct or indirect holding for Jason C. Jones?

The 1,308 Ekso Bionics shares from this transaction are held indirectly through a 401(k) account. The filing labels the ownership as “By 401(k)”, while a separate entry shows his directly held position of 25,621 common shares following the reported activity.

How does the reverse stock split affect the Ekso Bionics (EKSO) Form 4 share counts?

All share amounts in this Form 4 reflect a 1-for-15 reverse stock split effective June 2, 2025. The footnote explains the reported securities have been adjusted, meaning current holdings and the 1,308-share acquisition are shown on a post-split basis.